Stuttgart
13.10.25 | 11:17
1,622 Euro
-3,80 % -0,064
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ADVICENNE: Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities | 3 | Euronext | ||
| 19.09. | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 282 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08. | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 269 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 346 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07. | Advicenne Reports its H1 2025 Sales | 324 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07. | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 736 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 330 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 30.06. | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 370 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04. | ADVICENNE: Advicenne met à disposition son Document d'Enregistrement Universel 2024 | 2 | Euronext | ||
| 29.04. | Advicenne 2024 Universal Registration Document Made Available | 262 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 534 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 464 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 444 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 499 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 214 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,395 | +0,16 % | Wieder aufwärts - u.a. mit Hochtief, Merck, Pfizer, Sartorius - Börse München | Die deutschen Aktienbörsen haben in der vergangenen Woche überwiegend merklich zugelegt. Getrieben wurden die Kurse unter anderem von Hoffnungen auf weitere Zinssenkungen durch die US-Notenbank Fed... ► Artikel lesen | |
| ABBVIE | 198,60 | 0,00 % | Abbvie - ABBV: Berenberg-Bank JETZT mit "KAUFEN"! | Kursziel 270 USD! Skyrizi & Rinvoq lösen Humira als Umsatzbringer für Abbvie ab! Marktführer bei Immunologie! Abbvie (ABBV) - ISIN US00287Y1091 Rückblick: Mit einem Kursplus von rund 30 Prozent beeindruckte... ► Artikel lesen | |
| HALEON | 3,923 | +1,03 % | Haleon plc and Salesforce: Haleon wählt Salesforce Agentforce und Life Sciences Cloud for Customer Engagement, um die Zusammenarbeit mit Apotheken und medizinischen Fachkräften mittels KI zu verbessern | Haleon plc (LSE/NYSE:HLN), ein führendes globales Verbraucherunternehmen mit Schwerpunkt auf der täglichen Gesundheit, und Salesforce (NYSE:CRM), die weltweite Nummer 1 für KI-CRM, gaben heute bekannt... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,775 | +4,13 % | ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report | ||
| LIGAND PHARMACEUTICALS | 154,00 | +0,65 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ROYALTY PHARMA | 31,030 | +0,06 % | Dividende und Wachstum? Das geht! Mit RE Royalties, Royalty Pharma oder Evonik | An der Börse geht es nicht nur um Kurssteigerungen, auch Dividenden sind ziemlich attraktiv. Es gibt sogar professionelle Anlegergruppen, die sich fast ausschließlich auf kontinuierliche Erträge fokussieren.... ► Artikel lesen | |
| EISAI | 24,630 | -0,48 % | Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease | New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an... ► Artikel lesen | |
| TG THERAPEUTICS | 29,170 | +0,31 % | H.C. Wainwright initiates TG Therapeutics stock with Buy rating on MS drug growth | ||
| DR REDDYS | 12,300 | 0,00 % | Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior ... | ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr.... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,032 | -7,35 % | BetterLife Pharma Inc.: BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders | VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on... ► Artikel lesen | |
| KYOWA KIRIN | 12,600 | 0,00 % | Kura Oncology, Inc.: Kura Oncology And Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition Of Npm1 And Flt3 Mutations In Patients With Newly Diagnosed Acute Myeloid Leukemia (aml) | - Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML - - FLT3 mutations occur in approximately 30%... ► Artikel lesen | |
| IGC PHARMA | 0,350 | 0,00 % | IGC Pharma, Inc.: IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders | POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,500 | -0,76 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency | Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) ... ► Artikel lesen | |
| IMMUPHARMA | 0,108 | -8,47 % | Immupharma PLC - Appointment of Independent Non-Executive Director | ||
| OPTINOSE | 8,600 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 21.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.05.2025.ISIN NameCA00829Q1019 AFRICA... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.